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OBJECTIVES: A model assessing sequential olfactory testing and dopamine trans-
porter (DAT) imaging for screening pre-motor Parkinson’s Disease (PD) was
adapted to a European setting with German cost and health utility data.METHODS:
PD Associated Risk Study (PARS) data were used to parameterize screening efficacy.
Screening strategies in persons 1) in a general population, 2) with a relative with PD,
3) with LRRK2 genotype, and 4) with REM sleep disorder were evaluated. PD prev-
alence per 100 at screening was 0.5, 2, 10 and 20 for these groups. Olfactory test and
DAT costs were €11 and €1500, respectively. We assumed disease modifying (DM)
therapy was available that slowed disease progression by 20% at a cost of €30,000.
Economic value was measured in net monetary benefits (NMB), valuing a quality-
adjusted life-year at €50,000. RESULTS: Screening sensitivity and specificity were
64% and 99%, respectively. 13.4% had positive results on the olfactory test and also
took the DAT. NMB for the four groups was €-169, €269, €2,603, and €5,521, indicat-
ing that screening has positive economic value in persons with a close relative with
PD, persons with LRRK2 genotype, and persons with REM sleep disorder. Screen-
ing value was positively correlated with rate of progression from preclinical to
clinical PD, efficacy of DM therapy, and QALY monetization. Screening value was
negatively correlated with costs of false positives, screening cost, age at onset,
Hoehn and Yahr stage at which the unscreened diagnosis is made, and cost of DM
therapy. CONCLUSIONS: Screening for early PD may be a cost-effective strategy for
certain risk groups.
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OBJECTIVES: New diagnostic approaches, including molecular profiling, have im-
proved the ability to establish accurate diagnoses of hematologic cancers, but have
also increased the complexity of test ordering, information integration and inter-
pretation. This study examined the role of specialty and other laboratory providers,
the types of diagnostic tests provided for patients with suspected hematologic
cancers, and subsequent health care costs. METHODS: Patients with bone marrow
biopsies and suspected hematologic cancer/condition (2005-2011) were identified
from claims data from a large US health plan. Included patients had 6 pre- &
3-months post-biopsy health plan coverage. Lab tests in the 30 days post-biopsy
were identified. Patient cohorts were based upon laboratories performing marrow
morphologic assessment/directing testing sequence: Genoptix (GX, a specialty he-
matology-testing laboratory); large commercial laboratories (LL), other laboratories
(OL); academic labs were excluded. Diagnostic/treatment medical costs (per-pa-
tient-per-month) during the 30-days & 1 year post-biopsy were examined (ANOVA).
RESULTS: Of 30,393 patients with suspected hematologic malignancy/condition,
94.25% had marrow morphology reviewed. OL patients were slightly younger (58.19
OL vs. , 59.88 GX, 59.39 LL, P0.001). More flow cytometry was done at GX (96.68%)
vs 87.68% in LL and 69.78% in OL. Cytogenetics/FISH analysis rates were: 95.96% GX,
80.78% LL, 51.68% OL. Use of molecular diagnostics was less common (26.03% in GX,
14.27% in LL and 9.31% in OL). 1-year PPPM costs were $4487 GX, $4325 LL, and $5407
OL (P0.001)); costs PPPM excluding the testing period were $2132 GX, $2686 LL, and
$3341 OL (P0.001). CONCLUSIONS: Frequency of diagnostic tests in the 30-days
post-biopsy varied, with complex tests conducted more frequently in the hematol-
ogy specialty laboratory. However, disease-related costs with the specialty labora-
tory were lower than costs for some laboratories with lower use of these tests.
Further exploration of the impact of alternative diagnostic testing approaches on
costs and clinical outcomes is warranted.
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OBJECTIVES: Due to high cost and limited availability of dual-energy x-ray absorp-
tiometry (DXA), 77 percent of high risk population remains undiagnosed and there-
fore untreated for osteoporosis. To cope up with current scenario, pre-screening
tools have become apparent as pragmatic tool for extensive screening of osteopo-
rosis. Use of such tools would help health care professionals to make better use of
bone densitometry and to cut billions of dollars cost associated with DXA. This
study attempts to evaluate possible reasons that pose hindrance in implementa-
tion of such tools despite of reliability and cost effective nature of such tools.
METHODS: Using convenience sampling method, a pre-validated questionnaire
was used to conduct a cross-sectional survey among health care professionals in
Malaysia. 5 endocrinologists, 10 orthopedic specialists, 25 medical officers, 30 hos-
pital pharmacists participated from Hospital Pulau Penang while 33 community
pharmacists and 27 general practitioners from Penang participated in survey(total
130). RESULTS: There was no statistically significant difference regarding knowl-
edge of pre-screening tools among health care professionals belonging to different
specialties. Although, 77% of participants have heard about pre-screening tools but
only 53 % were able to identify the purpose of such tools. Out of list of 8 pre-
screening tools, majority 36 % identified SCORE followed by MOST (22 %) as pre-
screening tools while other tools were not identified. Only 5 % of participants have
used such tools while 94 % showed willingness to use such tools and to encourage
patients to undergo screening by such tools. Majority 61 % preferred leaflets/ bro-
chures to gain information regarding availability and utility of such tools while
least 13 % preferred continuous education programs. CONCLUSIONS: Proper
awareness regarding availability and utility of such tools would not only help to
improve patient’s quality of life also it would help to reduce global economic bur-
den associated with osteoporosis.
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OBJECTIVES: Few data exists on high cardiovascular risk (HCVR) prevalence within
a primary prevention population. The goal of the study was to assess HCVR distri-
bution, according to the European SCORE risk assessment scale, in France in high-
risk primary care patients not treated with lipid-lowering drug. METHODS: This
observational study was conducted over a week on a representative sample of
French general practitioners (GP). All consulting primary care men/women 50/60
y, with at least one other CVR factor (smoking, high blood pressure (HBP), type 2
diabetes, HDL-c0.40 g/L), not treated for dyslipidemia were included in the study.
GP filled-in an on line questionnaire that enabled SCORE calculation. RESULTS:GPs
(n1147) included 9049 patients (mean age: 68 y; male: 57%; LDLc1.3 g/L: 57%;
smoking: 21%; HBP: 44%; type 2 diabetes: 21% HDL-c0.4 g/L: 16%). According to
SCORE, HCVR prevalence reached 50% in total population (male: 49%, female: 51%).
50% of HCVR men/women were older than 72.4/78.8 y. HCVR patients were older
by 7.7/6.8 y for male/female (p 0.01) than non-HCVR patients. Other significantly
more frequent characteristics in high CVR population are: HDL0.6 g/L (38%), un-
treated or uncontrolled HBP (53%) and left ventricular hypertrophy (8%). Obesity is
less frequent (15%) in high CVR population. Highest HCVR prevalence was observed
in the Mediterranean population (54%), and lowest (47%) in the Northeast popula-
tion (p 0.01). Adjustment by age and gender reduces regional disparities (52% vs
48%).CONCLUSIONS:Half consulting primary care patients aged50/60 y for men/
women with at least 1 risk factor on top of age and no lipid-lowering treatment are
at HCVR according to SCORE risk equation. Assessing cardiovascular risk with risk
equations appears particularly useful in this group of patients. Besides age, which
has the strongest impact on risk estimation, other RF may be screened to improve
HCVR management.
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OBJECTIVES: To systematically review the current clinical and cost-effectiveness
literature of third-generation, implantable left ventricular assist devices (LVADs)
for people with end-stage heart failure (ESHF). METHODS: Three implantable,
third-generation LVADs were identified as available in the EU. A systematic litera-
ture review was conducted of published and unpublished cost-effectiveness and
clinical data (comparative studies) in the ESHF population, since their inception till
April 2012, using a number of medical databases. RESULTS:One relevant economic
evaluation and four comparative clinical studies (1 vs. virtual control arm & 3 vs.
older-generation LVADs) met the inclusion criteria. Therapy success defined as
survival LVAD or explant to receive a heart transplant or for recovery, occurred in
approx. 92.0% of patients with third-generation LVADs and 90.1% of control pa-
tients (second-generation LVAD) in a 6-months period. The 1-year survival of pa-
tients who were implanted with third-generation LVADs ranged from 82% to 91%.
The most frequently reported adverse events were arrhythmias, bleeding, infec-
tion, respiratory and renal failure, right heart failure, and stroke. One included
study evaluates the cost-effectiveness of the implantable, third-generation LVADs
as destination therapy for patients with ESHF as compared to patients on medical
management in the UK. Results showed that at 5ys LVADs had an additional cost of
about £20,500 per patient and QALY gain of 1.05, giving an incremental cost per
QALY of £19 500, which is below the commonly adopted threshold of £25,000 per
QALY. However, this finding seems unreliable due to controversial assumptions.
CONCLUSIONS:Despite the poor methodological quality of included studies, third-
generation of implantable LVADs seems beneficial due to improving survival, ther-
apy success and functional status. Adverse events serious concern. No prospective
controlled data are available as bridge to recovery, nor destination therapy. There
is an urgent need for additional, reliable cost-effectiveness studies evaluating
third-generation pumps versus previous generations of LVADs.
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OBJECTIVES: To assess the clinical effectiveness of extracorporeal photopheresis
(ECP) in the treatment of acute or chronic steroid-refractory graft versus host dis-
ease (GvHD). METHODS: Clinical effectiveness of the analysed intervention was
evaluated in accordance with the principles of systematic review based on the
Cochrane Collaboration guidelines (Cochrane Reviewer’s Handbook) and the guide-
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lines of Polish Agency for Health Technology Assessment. RESULTS: As a result of
a systematic search of publications, one single-blind, randomized clinical trial
(Flowers 2008), fulfilling the predefined inclusion criteria, was found. The trial di-
rectly compared the clinical effectiveness of extracorporeal photopheresis com-
bined with conventional therapy vs conventional therapy alone in the treatment of
cutaneous cGvHD that could not be controlled by steroids. Moreover, there were
identified 45 non-randomised, single-arm clinical trials which assessed the clinical
effectiveness of ECP in analysed indications. Based on identified clinical trials it
could be concluded that there is clinically relevant response to ECP treatment
among patients with acute or chronic GvHD. The highest improvement was ob-
served in skin, liver and gut among patients with aGvHD and in skin but also in
mucosa, liver and lungs involvement among patients with cGvHD. Moreover, it was
showed that ECP treatment is connected with reduction in the use of immunosup-
pressant (mainly steroids) in both groups of patients: with acute or chronic steroid-
refractory or steroid-dependant GvHD. The reduction in steroid dose allows to
reduces the risk of life-threatening bacterial, viral and fungal infections. ECP is very
well tolerated procedure. Infrequent adverse events are usually mild and seldom
led to discontinuation of the treatment. CONCLUSIONS: Results obtained from
clinical trials included in the systematic review showed that there exists clinical
benefit associated with the use of ECP in the treatment of pediatric and adult
patients with steroid-refractory, steroid-dependant acute or chronic GvHD.
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OBJECTIVES: To evaluate real-world effectiveness and device complication out-
comes of the LAP-BAND AP® System adjustable gastric band (LAGB) one year after
surgical implantation. METHODS: HERO study is a 5-year registry of 1,106 severely
or morbidly obese subjects from 29 centers in North America, Europe, and Australia
implanted with LAGB. In the current analyses, the mean change in body mass
index (BMI) and percentage excess weight loss (%EWL) at 1 year are determined.
Rates of device complication events as well surgical revisions and explants at 1 year
are also reported. RESULTS: The mean age of subjects was 43.1 years and females
constituted 79.3%. The mean(SD) weight and BMI at baseline was 126.2(24.1) kg and
45.1(6.9) kg/m2 respectively. At 1 year, the mean (SD) BMI decreased by 7.7(4.4)
kg/m2 and the average(SD) %EWL was 39.8(22.3)%. One (0.1%) death occurred from
liver cancer and was deemed not related to the device. Of 47 subjects with 53 device
complication events at 1 year, 18 (1.6%) experienced an event at 3-months, 9 (0.8%)
at 6-months, and 20 (1.8%) at 1-year. Subjects who reported device complications
were port displacement (1.8%), pouch dilatation (0.8%), band erosion (0.5%), device-
related infection (0.5%), band slippage (0.4%), port leak (0.1%), and both band slip-
page and pouch dilatation (0.3%). Eighteen (1.6%) subjects had explants and 3 (0.3%)
had the LAGB surgically revised and replaced. The indications for explants in-
cluded band erosion, band slippage, band intolerance, esophageal dilatation,
pouch dilatation, device-related infection, abdominal pain, dysphagia, and small
bowel obstruction. Minor device related revisions included access port revision
23(2.1%) and reposition of LAGB 4(0.4%). CONCLUSIONS: LAGB was associated with
significant weight loss, with less than 2% of subjects undergoing explantation of
the device within year 1 of this 5-year on-going study. Many reported device com-
plications were considered to be non-serious and could be corrected in an outpa-
tient setting.
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OBJECTIVES:After decades of warfarin as the dominant strategy for stroke preven-
tion in atrial fibrillation (SPAF), new treatments are available. These include new
pharmaceuticals like dabigatran etexilate and a device based approach, left atrial
appendage closure (LAAC). Studies have compared the economics of pharmaceu-
tical treatments, but the cost implications of the device-based approach with high
initial procedural costs compared to these new drugs, with high annual costs for
life, have not been demonstrated. This analysis compares overall costs of SPAF
with LAAC to dabigatran 110mg twice daily.METHODS:An Excel-based cost impact
model was developed using data from PROTECT-AF (Holmes 2009) and RE-LY clin-
ical trial (Connelly 2009), both of which evaluated patients with a CHADS2 score1.
These studies reported similar rates of adverse events, with the exception of bleed-
ing events which were more frequent in dabigatran patients. The model captures
all costs associated with treatment, discontinuation of care and complications.
Costs were based on the German system, using published DRGs and tariffs associ-
ated with procedures, drugs, and disability care. RESULTS: First year average per
patient cost of LAAC was €11,076 compared to €3,251 for dabigatran. However, the
overall cost of care at 5 years for LAAC (€13,547) was less than dabigatran (€13,675)
due to higher annual drug and complication costs in the dabigatran arm.
CONCLUSIONS: Although LAAC was higher cost than dabigatran in the first year,
the total cost of care for dabigatran increased substantially each year, compared to
only modest annual costs for LAAC past the first year. The full burden of costs
associated with dabigatran is higher than with LAAC after five years and continues
to accrue due to high regular annual costs. This is an important consideration for
budget holders in evaluating lifetime treatment when many AF patients are now
living into their eighties and beyond.
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OBJECTIVES: Major practice changes require both clinical and economic rationale,
especially where a novel device replaces an established pharmaceutical therapy.
Recent studies have reported the clinical benefits of percutaneous left atrial ap-
pendage closure (LAAC) for stroke prevention in atrial fibrillation (SPAF) as com-
pared to standard warfarin anticoagulation, but the cost implications of the device-
based approach have not yet been demonstrated. This analysis highlights the
ongoing costs of complications associated with a long standing pharmaceutical
therapy compared to a device-based approach. METHODS: An Excel-based cost
impact model was developed using data from the PROTECT-AF clinical trial which
randomized 707 AF patients to either LAAC or warfarin (Holmes 2009). The model
captured the costs of complications in AF, including strokes, systemic embolism,
major extracranial bleeding and complications associated with the LAAC proce-
dure. Costs for stroke included only the acute, direct costs and did not capture the
long-term societal costs associated with disability. Germany, which recently rec-
ognized the LAAC procedure with a unique DRG code, was the basis for costs, using
published DRGs and tariffs associated with procedures, drugs, and care. RESULTS:
The high rate of adverse events in the warfarin arm generated €6,414 in medical
costs for complications per patient at 5 years, compared to €3,276 for LAAC. These
included mean costs of €3,239 for stroke and systemic embolism and €970 for major
bleeding in the warfarin arm, compared to €1,551 and €484 respectively for LAAC.
The mean annual cost of complications for warfarin was roughly twice that of
LAAC, (€1,283 versus €655). CONCLUSIONS: The complication cost differential
highlights the need for decision makers to consider the totality of long-term costs
and clinical implications of lifetime treatment strategies for SPAF.
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OBJECTIVES: To model the financial impact for the health care institution of spec-
imen rejection due to preanalytical errors in the laboratory testing phase, using
institution specific data. METHODS: Critical data such as number of beds; overall
budget; number of patients of different types seen each year; and number of sam-
ple rejections, as well as qualitative data, eg. probable impact of sample rejection
were collected by interviewing institution staff from multiple country institutions
(N10). The data were then entered into a model to calculate the possible financial
impact of laboratory sample rejections. The model separates patients into different
groups according to the likely effects of having a sample rejected, the probability
that the rejection would have a low, medium or high impact and the consequences
on institution time and resources. The overall consequence, or opportunity cost,
was expressed as patient treatment time and financial cost. RESULTS: The size of
the institutions ranged from 326 to 1,200 beds, with total operating costs varying
between €41 million and €1.1 billion. The number of blood tests per month was
between 37,000 and 458,000 and of these between 0.09% and 2% were rejected
(mean 0.93%). The total cost of specimen rejection ranged from €22k to €5.9 million
per annum (mean €1.9 million), equating to a percentage of total operating costs
from 0.1% to 1.2% (mean 0.4%). The estimated cost per patient for a sample rejec-
tion was from €29 to €349 (mean €171). CONCLUSIONS: A customisable model
allows institutions to estimate, using local data and assumptions, the effect of
sample rejection on patient treatment and cost. Results can be compared to those
from other institutions to benchmark performance and assumptions. The results
demonstrated that a reduction in the number of rejected samples due to preana-
lytical errors could lead to significant cost savings for most institutions.
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OBJECTIVES: Needlestick injuries (NSIs) represent a significant clinical and eco-
nomic burden to health care systems and society. The EU Directive on the preven-
tion of sharps injuries recommends adherence to a range of safety measures, of
which providing safety-engineered devices (SEDs) forms a key part. An economic
model was constructed to investigate the potential hospital budget savings asso-
ciated with the use of SEDs rather than conventional (i.e. non-safety-engineered)
devices when conducting procedures with sharp devices. METHODS: An inci-
dence-based, deterministic budget impact model with a five-year time horizon was
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